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Background: There are no long-term data with CMRI regarding intracoronary bone marrow cell (BMC) therapy after acute myocardial infarction (AMI).
Methods: We performed a double-blind, placebo-controlled, randomized trial in AMI patients (NCT00669227). Patients were randomized to BMC 
versus placebo therapy in a 2:1 ratio and stratified according to age, AMI localization and LV function. Mononuclear cells for active treatment were 
isolated with Ficoll density gradient centrifugation (Cambrex, Belgium). Serial CMRI studies were performed: prior study therapy and at 1, 3, 6, 12, 24 
and 36 months follow-up. Primary endpoint was difference in LVEF between baseline and 6 months.
Results: 29 patients were randomized to BMC and 13 to placebo treatment. A mean number of 381*106 mononuclear BMCs were administered 
median 6.1 days after onset of AMI. Baseline data did not differ. As compared to baseline the difference in LVEF for placebo versus BMC treatment 
at 1 month was 1.7±6.4% vs. -0.9±5.5% (p=0.20), 3 months 3.1±6.0% vs. 1.9±4.3% (p=0.53), 6 months 5.7±8.4% vs. 1.8±5.3% (p=0.09; primary 
endpoint with subsequent inclusion stop due to pre-specified stopping rules), 12 months 1.6±7.8% vs. -1.4±6.4% (p=0.22), 24 months 1.9±9.1% 
vs. -2.6±6.0% (p=0.09), and at 36 months 2.0±9.4% vs. -1.7±5.8% (p=0.20), respectively. There was no difference between groups in LVEDVI, 
LVESVI and infarct size at every CMRI study. Differences in CMRI between baseline prior to study therapy and 36 months for placebo versus BMC 
treatment were for LVEDVI -3.5±14.8mL/m2 vs. 1.8±8.8mL/m2 (p=0.70), for LVESVI -1.7±10.1mL/m2 vs. 0.7±6.9mL/m2 (p=0.46), and for infarct 
size -12.9±6.9% vs. -12.1±5.9% (p=0.76).
Conclusions: In this rigorous double-blind, randomized, placebo-controlled trial we did not observe an evidence for a positive effect for 
intracoronary BMC as compared to placebo therapy with respect to LVEF, LV volume indices and infarct size determined by six serial CMRI studies 
within a 36 months period.
